UC Davis Health Ventures, part of the Innovation and Economic Development Office (IEDO) at the University of California, Davis, today announced the first investment from its Investing in the Future of Medicine (IFM) Fund, backing Delix Therapeutics. Delix, a UC Davis spinout, is developing non-hallucinogenic neuroplastogens for major depressive disorder (MDD) and other serious neuropsychiatric and neurodegenerative conditions.
Delix’s science originated at UC Davis in the laboratory of Professor David E. Olson. His research separated the therapeutic effects of psychedelics from hallucinogenic properties and led to next-generation, non-hallucinogenic compounds designed to rapidly promote neuroplasticity. Now in clinical trials, Delix’s lead candidate DLX-001, Zalsupindole, has reported favorable Phase 1a safety and tolerability, as well as proof of central nervous system…
